Design Assurance Engineer 2

Fractyl Health Inc reported a net loss of $43.7 million for Q4 2025, compared to $25 million in the prior year period, with adjusted EBITDA of negative $21.2 million. The company held approximately $81.5 million in cash and cash equivalents as of 31 December 2025, expected to fund operations into early 2027. Research and development expenses decreased to $16.5 million from $20.3 million year-over-year, whilst SG&A expenses rose to $6.8 million from $4.9 million. The company received favourable FDA feedback on its de novo classification request for Revita, its post-GLP-1 weight maintenance device, indicating potential Class II classification. Fractyl's pivotal study for Revita demonstrates over 90% confidence in achieving primary endpoints, though six-month data showed variability in treatment effects.

Fractyl Health appoints Lara Smith Weber as Chief Financial Officer to support commercial-stage preparedness. Rhea-AI summary. Fractyl Health (Nasdaq: GUTS) announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026, to lead finance, accounting, and investor relations as the company prepares for commercial-stage operations. The release notes Ms. Smith Weber brings 20+ years of financial leadership in medtech and biotech, prior CFO roles at Inari and ONWARD Medical, and experience preparing organizations for commercialization. Longtime CFO Lisa Davidson resigned effective December 31, 2025 and will provide consulting support during the transition. * New CFO Lara Smith Weber starts on Jan 12, 2026 * Incoming CFO has 20+ years of medtech/biotech financial leadership * Resigning CFO will provide transition consulting support * CFO transition occurred immediately after Dec 31, 2025 resignation On the day this news was published, GUTS declined 2.91%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $271M at that time. Data tracked by StockTitan Argus on the day of publication. Key figures. CFO start date January 12, 2026 Effective date for Lara Smith Weber as CFO Prior CFO tenure 10 years Lisa Davidson's tenure as Fractyl's CFO Experience length More than 20 years Lara Smith Weber's financial leadership experience Technical Shares at $2.06 are trading above the 200-day MA of $1.50, despite a -8.44% move in the prior session. Peers on Argus. GUTS fell 8.44% while peers were mixed: ADVM gained 2.83%, but IMMX, ACET, and ALGS declined roughly 7 - 8%, and XFOR slipped 1.54%. The pattern suggests stock-specific factors rather than a uniform sector move. Recent news with clear clinical or financing implications often aligned with positive price reactions, while structurally important capital actions sometimes saw muted or divergent moves. Over the last few months, Fractyl reported several milestones. On Nov 12, 2025, Q3 results highlighted clinical progress and cash runway, with a modestly positive share reaction. Positive REVEAL-1 weight maintenance data on Dec 2, 2025 drove a 17.95% gain. An offering-related warrant call on Dec 15, 2025 generated no next-day move. Against this backdrop of clinical and financing updates, the CFO transition reflects ongoing organizational scaling rather than a new clinical or capital event. Market pulse summary. This announcement highlights a CFO transition as Fractyl prepares for potential commercial-stage operations. The new CFO brings 20+ years of experience in growth-focused medtech and biotech, while the outgoing CFO remains as a consultant to support continuity. Set against recent clinical progress and financing activities, this leadership move underscores an emphasis on financial discipline, operational scaling, and readiness for future pivotal and commercialization milestones. BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) - Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company's executive leadership team and Board of Directors. Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a strong track record of building disciplined financial organizations, supporting transitions into commercial-stage operations, and guiding companies through periods of operational scale with increasing regulatory and public-market complexity. "Fractyl is entering a stage where disciplined execution and commercial preparedness become increasingly important," said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl. "Lara's experience building financial and operating discipline in growth-stage healthcare companies makes her well-suited to support the Company as we advance through pivotal development and prepare for commercial execution and scale." Most recently, Ms. Smith Weber served as Chief Financial Officer of Inari, where she completed multiple financings, strengthened the company's capital structure, and built financial systems and processes to support a growing organization. Previously, she was Chief Financial Officer of ONWARD Medical, a publicly traded medtech company listed on Euronext. Earlier in her career, Ms. Smith Weber served as U.S. Chief Financial Officer and Head of Commercial Finance at MorphoSys, where she played a key role in preparing the organization for and operating as a commercial-stage company. "Fractyl is at a pivotal moment as the Company works to redefine what is possible in the treatment of metabolic disease," said Ms. Smith Weber. "The opportunity to move beyond chronic management toward durable remission represents a meaningful shift for patients and for the healthcare system. I'm excited to join the team as Fractyl advances its clinical programs and prepares for the operational and financial scale needed to support commercialization, with a focus on disciplined capital allocation and long-term value creation." After ten years with the Company, Lisa Davidson has resigned as Fractyl's Chief Financial Officer effective as of December 31, 2025. During her tenure, Ms. Davidson played a central role in guiding Fractyl through key periods of growth, including its initial public offering, strengthening financial and operating disciplines, and supporting the buildout and scaling of the Company's facilities and infrastructure. Ms. Davidson will provide consulting services to the Company during this transition. "Lisa has been a steady and trusted partner to me and to the leadership team," said Dr. Rajagopalan. "Her rigor, integrity, and thoughtful leadership have helped position Fractyl for its next phase, and we are grateful for her many contributions to the organization." About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl's goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 35 granted U.S. patents and approximately 45 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's executive leadership transition, including the anticipated contributions of the Company's new Chief Financial Officer. These forward-looking statements are based on management's current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the Company's ability to effect an orderly leadership transition and execute its strategic objectives. Additional risks and uncertainties are discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025, and in our other filings with the SEC. These forward-looking statements are based on management's current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change. Who is the new CFO of Fractyl Health (GUTS) and when does she start? Lara Smith Weber is the new CFO and will be effective on January 12, 2026. Why did Fractyl Health (GUTS) appoint Lara Smith Weber as CFO? The company said she brings 20+ years of financial leadership and experience preparing companies for commercial-stage operations. When did Fractyl Health's previous CFO leave and will she assist the company? Lisa Davidson resigned effective December 31, 2025 and will provide consulting services during the transition. What responsibilities will Lara Smith Weber have as CFO of Fractyl Health (GUTS)? She will oversee finance, accounting, and investor relations and serve as a strategic partner to leadership and the board. Does the CFO change signal Fractyl Health (GUTS) moving toward commercialization? The company links the hire to preparing for commercial-stage preparedness and operational scale.